NewCardio (NWCI.OB) Appoints Three New Executives to their Client Services Team
NewCardio is in the business of saving lives while reducing costs. The company is developing a patent pending electrocardiography (ECG) platform technology to dramatically improve the diagnostic accuracy and value of the standard 12 lead ECG for common acute and chronic heart disease. Also, the advancement in 3D technology from NewCardio can stave off errors in interpreting the standard 2D 2-lead ECG. Errors of “major proportions” have been identified in 4% to 32% of ECG interpretations. The NewCardio Client Services Team has three new additions, which will enhance the team’s efforts to provide clients with the high quality service that…